REDHILL BIOPHAR/S ADR (NASDAQ:RDHL) had its Buy rating reiterated by HC Wainwright

ME Staff
-
0

Analyst Ratings For REDHILL BIOPHAR/S ADR (NASDAQ:RDHL)

Today, HC Wainwright reiterated its Buy rating on REDHILL BIOPHAR/S ADR (NASDAQ:RDHL).

There are 5 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings, no Hold Ratings on the stock.

The current consensus rating on REDHILL BIOPHAR/S ADR (NASDAQ:RDHL) is Buy with a consensus target price of $22.60 per share, a potential 198.55% upside.

Some recent analyst ratings include

  • 7/31/2018-HC Wainwright Reiterated Rating of Buy.
  • 6/25/2018-LADENBURG THALM/SH SH initiated coverage with a Buy rating.
  • 1/26/2018-Nomura initiated coverage with a Buy rating.
  • 10/6/2017-Seaport Global Securities initiated coverage with a Buy rating.
  • 9/13/2017-UBS Group initiated coverage with a Reduce rating.
  • 6/16/2017-FBR & Co Reiterated Rating of Buy.


    About REDHILL BIOPHAR/S ADR (NASDAQ:RDHL)
    RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs. Its principal clinical-stage development programs comprise TALICIA (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria infections; BEKINDA (RHB-102) for acute gastroenteritis and gastritis and diarrhea-predominant irritable bowel syndrome; YELIVA (ABC294640) for cholangiocarcinoma, as well as targeting other oncology, inflammatory, and gastrointestinal indications; RHB-106, an encapsulated bowel preparation; and RHB-107 for cancer and inflammatory gastrointestinal diseases. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

    Recent Trading Activity for REDHILL BIOPHAR/S ADR (NASDAQ:RDHL)
    Shares of REDHILL BIOPHAR/S ADR closed the previous trading session at 7.52 −1.23 14.06% with 7.48 shares trading hands.